References
- Tiihonen J, Haukka J, Taylor M, et al. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry. 2011;168(6):603–609.
- Abilify Maintena, Summary of Product Characteristics, European Medicine Agency. 2016. [cited 2016 Jul 21]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR__Product_Information/human/000471/WC500020170.pdf
- Abilify Maintena US prescribing information. [cited 2016 Jul 21]. Available from: https://www.otsuka-us.com/media/static/Abilify-M-PI.pdf
- Croxtall JD. Aripiprazole: a review of its use in the management of schizophrenia in adults. CNS Drugs. 2012 1;26(2):155–183.
- Naber D, Hansen K, Forray C, et al. Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia. Schizophr Res. 2015;168(1–2):498–504.
- Kane JM, Peters-Strickland T, Baker RA, et al. Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2014;75(11):1254–1260.
- Oya K, Kishi T, Iwata N. Efficacy and tolerability of aripiprazole once monthly for schizophrenia: a systematic review and meta-analysis of randomized controlled trials. Neuropsychiatr Dis Treat. 2015;11:2299–2307.
- Kahn RS, Giannopoulou A. The safety, efficacy and tolerability of abilify maintena for the treatment of schizophrenia. Expert Rev Neurother. 2015;15(9):969–981.
- Shirley M, Perry CM. Aripiprazole (Abilify Maintena®): a review of its use as maintenance treatment for adult patients with schizophrenia. Drugs. 2014;74(10):1097–1110.
- Alphs L, Benson C, Cheshire-Kinney K, et al. Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: a randomized, open-label, review board-blinded 15-month study. J Clin Psychiatry. 2015;76(5):554–561.
- Fleischhacker WW 1, Sanchez R, Johnson B, et al. Long-term safety and tolerability of aripiprazole once-monthly in maintenance treatment of patients with schizophrenia. Int Clin Psychopharmacol. 2013;28(4):171–176.
- Brissos S, Ruiz Veguilla M, Taylor D, et al. The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. Ther Adv Psychopharmacol. 2014;4(5):198–219.
- Mallikaarjun S, Kane JM, Bricmont P. Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose study. Schizophr Res. 2013;150(1):281–288.
- De Filippis S, Cuomo I, Lionetto L, et al. Intramuscular aripiprazole in the acute management of psychomotor agitation. Pharmacotherapy. 2013;33(6):603–614.
- Abilify injection, highlights of prescribing information. [cited Aug 12]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021436s038,021713s030,021729s022,021866s023lbl.pdf
- Committee for Medicinal Products for Human Use. Abilify Maintena EMA Public Assessment Report (EPAR). European Medicines Agency. [cited 2016 Jul 20]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Public_assessment_report/human/002755/WC500156105.pdf
- Raoufinia A, Baker RA, Eramo A, et al. Initiation of aripiprazole once-monthly in patients with schizophrenia. Curr Med Res Opin. 2015;31(3):583–592.
- Correll CU. From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. Eur Psychiatry. 2010 Jun;25(Suppl 2):S12–S21.
- Fagiolini A, Alfonsi E, Amodeo G, et al. Switching long acting antipsychotic medications to aripiprazole long acting once-a-month: expert consensus by a panel of Italian and Spanish psychiatrists. Expert Opin Drug Saf. 2016;15(4):449–455.